Traws Pharma, Inc. (NASDAQ:TRAW) Given Consensus Rating of “Reduce” by Brokerages

Traws Pharma, Inc. (NASDAQ:TRAW) has earned a consensus recommendation of “Reduce” from the five ratings firms that are presently covering the company, MarketBeat Ratings reports. Two analysts have rated the stock with a sell rating and three have issued a hold rating on the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $1.00.

A number of research firms have issued reports on TRAW. Citigroup cut Traws Pharma to a “neutral” rating in a research report on Monday, June 15th. LADENBURG THALM/SH SH cut shares of Traws Pharma from a “buy” rating to a “neutral” rating in a research note on Monday, June 15th. Weiss Ratings cut Traws Pharma from a “sell (d)” rating to a “sell (e+)” rating in a research note on Friday, May 29th. Wall Street Zen upgraded Traws Pharma from a “strong sell” rating to a “sell” rating in a research note on Saturday, June 13th. Finally, HC Wainwright reissued a “negative” rating and set a $1.00 price objective on shares of Traws Pharma in a report on Thursday, June 18th.

Traws Pharma Stock Up 2.0%

TRAW stock opened at $0.68 on Friday. Traws Pharma has a 12 month low of $0.64 and a 12 month high of $3.27. The firm has a market cap of $6.86 million, a P/E ratio of -0.40 and a beta of 1.51. The company’s 50-day moving average price is $1.26 and its two-hundred day moving average price is $1.56.

Traws Pharma (NASDAQ:TRAW) last released its earnings results on Friday, May 15th. The company reported ($0.53) earnings per share for the quarter, topping the consensus estimate of ($0.92) by $0.39. Equities analysts predict that Traws Pharma will post -1.43 EPS for the current year.

Insider Buying and Selling

In other news, major shareholder Orbimed Advisors Llc bought 597,729 shares of the company’s stock in a transaction on Thursday, April 16th. The stock was purchased at an average cost of $1.67 per share, for a total transaction of $998,207.43. Following the completion of the transaction, the insider owned 1,203,250 shares of the company’s stock, valued at $2,009,427.50. This trade represents a 98.71% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 7.57% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in TRAW. Squadron Capital Management LLC bought a new position in Traws Pharma in the 4th quarter valued at approximately $806,000. Ikarian Capital LLC grew its holdings in Traws Pharma by 2,280.0% during the 4th quarter. Ikarian Capital LLC now owns 678,142 shares of the company’s stock worth $766,000 after acquiring an additional 649,649 shares during the last quarter. Adage Capital Partners GP L.L.C. increased its position in Traws Pharma by 121.2% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 730,000 shares of the company’s stock valued at $825,000 after acquiring an additional 400,000 shares during the period. Boothbay Fund Management LLC acquired a new position in Traws Pharma in the 4th quarter valued at approximately $220,000. Finally, ADAR1 Capital Management LLC acquired a new position in Traws Pharma in the 4th quarter valued at approximately $175,000. Institutional investors and hedge funds own 7.95% of the company’s stock.

About Traws Pharma

Traws Pharma, Inc, a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.